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Background: Tumor interstitial fluid (TIF) rather than plasma should be used in cancer biomarker discovery
because of the anticipated higher concentration of locally produced proteins in the tumor microenvironment.
Nevertheless, the actual TIF-to-plasma gradient of tumor specific proteins has not been quantified. We present
the proof-of-concept for the quantification of the postulated gradient between TIF and plasma.
Methods: TIF was collected by centrifugation from serous (n = 19), endometrioid (n = 9) and clear cell (n = 3)
ovarian carcinomas with early (n = 15) and late stage (n = 16) disease in grades 1 (n = 2), 2 (n = 8) and 3
(n = 17), and ELISA was used for the determination of CA-125, osteopontin and VEGF-A.
Results: All three markers were significantly up-regulated in TIF compared with plasma (p b 0.0001). The TIF-to-
plasma ratio of the ovarian cancer biomarker CA-125 ranged from1.4 to 24,300 (median=194) andwas inversely
correlated to stage (p = 0.0006). The cancer related osteopontin and VEGF-A had TIF-to-plasma ratios ranging
from 1 to 62 (median = 15) and 2 to 1040 (median = 59), respectively. The ratios were not affected by tumor
stage, indicative of more widespread protein expression.
Conclusion: We present absolute quantitative data on the TIF-to-plasma gradient of selected proteins in the
tumor microenvironment, and demonstrate a substantial and stage dependent gradient for CA-125 between TIF
and plasma, suggesting a relation between total tumor burden and tissue-to-plasma gradient.
General significance: We present novel quantitative data on biomarker concentration in the tumor microenviron-
ment, and a new strategy for biomarker selection, applicable in future biomarker studies.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
As pathological tissues are perfused by blood and drained by lymph
vessels, locally secreted proteins are assumed to enter the circulation,
generating disease-specific signatures in the blood [1–5]. It is likely
that disease related biomarkers could be found in substantially higher
concentrations closer to the source, i.e. in the tumor microenvironment
[4,5]. Although the concentration gradient is hypothesized to be 1000-hylenediaminetetraacetic acid;
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. This is an open access article underto 1500-fold [4], the actual gradient between tumor interstitial fluid
(TIF) and plasma has to our knowledge not been quantified.
The exact quantification of potential gradients has been hampered
by the lack of suitablemethods for isolation of undiluted TIF. As recently
reviewed in Haslene-Hox et al. [6] andWiig & Swartz [7], most methods
used for TIF isolation, such as capillary ultrafiltration, microdialysis
and tissue elution add physiological buffer to extract proteins from the
interstitium. Accordingly, TIF will be diluted to an unknown extent,
preventing direct comparison of plasma and TIF concentrations.
The cancer antigen 125 (CA-125) is a high molecular weight
cell membrane glycoprotein, with a molecular weight N 500 kDa [8,9]
expressed by a variety of epithelial cells. It was introduced as the first
serum tumor marker test for ovarian cancer patients in 1983 [10–13].
CA-125 is to this date one of the few proteins that is routinely used
as a biomarker of cancer in the clinic and the reference standard for
validation of new biomarker candidates [14]. This protein is thought to
originate from the tumor tissue and a serum concentration N 35 U/mlthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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tissue has earlier been determined mainly in a semi-quantitative
manner by immunohistochemistry [15]. CA-125 concentration in
blood can also be used tomonitor recurrent disease in ovarian cancer
patients [16].
We also wanted to extend the quantification in TIF to include
additional proteins, and chose two proteins highly related to cancer in
general, that were likely to be produced in the tumor. VEGF-A, which
is central for angiogenesis and lymphangiogenesis in the body, and es-
pecially in cancer [17], and osteopontin, which [18] has been shown to
have a role in many steps of cancer development and is up-regulated
in many cancers [19]. Osteopontin has also been suggested as a bio-
marker for ovarian cancer [18,20] as well as renal cell [21], gastric and
liver carcinomas [22].
Utilizing the centrifugation technique developed by Wiig et al. [23,
24] to isolate native, undiluted TIF, we could determine the gradient of
tissue specific proteins from TIF to plasma. In this manner we could
demonstrate that the local production of the established ovarian cancer
biomarker CA-125 resulted in several orders of magnitude higher con-
centration in the tumor interstitium than in the plasma at early stage
disease. This is in contrast to the two smaller proteins osteopontin and
VEGF-A, known to be cancer specific and to be induced in several patho-
logical conditions [17,19], that do not show any stage-related
correlation in the present cohort.2. Materials and methods
2.1. Ethics statement
The research protocol has been approved by the Norwegian Data
Inspectorate (Protocol # 961478-2), Norwegian Social Sciences Data
Services (Protocol # 15501) and the Regional Committee for Medical
and Health Research Ethics (REK-Vest, Protocol ID REKIII nr. 052.01).
All sampleswere collected after obtaining the patients' written informed
consent. The work conformed to the standards set by the latest revision
of the Declaration of Helsinki.2.2. Collection of blood, ascites and TIF samples
Blood samples were collected from the patients 1–2 days before
surgery and EDTA was added as the anticoagulation agent prior to the
isolation of plasma by centrifugation. Ascites and tumor samples were
collected during surgery from patients operated for epithelial ovarian
cancer tumors at the Department of Obstetrics and Gynecology at
Haukeland University Hospital. Ascites were collected in centrifuge
tubes, centrifuged at 3220 g for 20min and the supernatantwas extract-
ed and stored at−80 °C until further processing. Tumor samples were
taken from the surface of theprimary tumors, in an areawithout any ap-
parent necrosis or inflammation. The surface region was selected for
sampling, as this has been shown to result in a lower contribution
from intracellular fluid to the isolated TIF [23]. Tumor samples
(0.2–0.5 g) for biobank storage were snap-frozen in liquid nitrogen
and transferred for storage at −80 °C. Tumor samples for TIF analysis
were placed on ice and transported to the laboratory. TIF was isolated
from the fresh tissue (tissue weight mean = 0.32 ± 0.02 g, range
0.13–0.53 g) approximately 60 min after extirpation by centrifugation
through a mesh-filter at 106 g for 10 min [23,24] and stored at
−80 °C until further processing. Samples larger than 0.5 g were cut in
multiple samples which were centrifuged in parallel. The isolated fluid
has earlier been validated as representative for interstitial fluid [24].
Selected samples were taken from the biobank and thawed and subse-
quently centrifuged as explained above (samples indicated by a in
Table 1). Two samples were used as references with fluid isolated
both from fresh and biobank tissue.2.3. Tissue elution
One sample (Patient no. 14, Table 1) with ample amounts of tumor
tissue was cut in two. One half was used for the isolation of TIF as
described above, and the other was eluted as described by Celis et al.
[24,25]. In brief, 0.31 g of tumor sample was washed in PBS, cut into
small pieces of approximately 1–3 mm3 and incubated at 37 °C in a
pre-weighed 15 ml conical plastic tube containing 1 ml PBS with
0.128 TIU aprotinin to inhibit proteolysis. After 1 h, 350 μl of eluate
was extracted (E1). The remaining buffer and tumor samplewas further
incubated overnight and the supernatant was extracted (E24). Both el-
uate samples were centrifuged immediately after extraction at 4622 g
for 20 min, and supernatants were frozen at−20 °C for later analysis.
2.4. ELISA analysis
Before CA-125 analysis, samples were diluted in 50 mg/ml bovine
serum albumin tomaintain a similarmatrix for all sample types. Plasma
and ascites were diluted 1:2, TIF 1:100 and eluates 1:20 (E1) and 1:34
(E24) to match the protein mass in plasma, to a total volume of 400 μl
for all samples. CA-125 concentration was measured with the Elecsys
CA 125 II tumor marker assay (Catalogue number 11776223 322,
Roche Diagnostics, Mannheim, Germany).
Osteopontin was quantified in plasma and TIF with an osteopontin
human ELISA kit (Cat. no. ab100618, Abcam, Cambridge, UK), following
the manufacturer's recommendations. Plasma was diluted 1:100 and
TIF was diluted 1:1000 in buffer A and run in duplicate. Briefly, samples
and standards were added to the coated 96-well plate and gently rotated
overnight at 4 °C. The plate was washed four times with washing solu-
tion, and incubated with biotinylated osteopontin detection antibody for
1 h. Subsequently, the plate was washed and incubated for an additional
45 min with HRP–streptavidin solution. The washing step was repeated,
and One-Step reagent solution was added and the plate was incubated
in the dark for 30 min. Finally, the stopping solution was added and the
optical density was read spectrophotometrically at 450 nm.
VEGF-A was quantified in plasma and TIF with a VEGF-A human
ELISA kit (Cat. no. ab100662, Abcam, Cambridge, UK), following the
manufacturer's recommendations, and as briefly summarized for osteo-
pontin. Plasma was diluted 1:10 and TIF was diluted 1:100 in buffer A
and run in duplicate.
2.5. Data and statistical analysis
GraphPad Prism (Software version 6.0, GraphPad Software Inc., La
Jolla, CA) was used for statistical analysis. p ≤ 0.05 was considered
statistically significant when not stated otherwise. Values are given as
mean±SEM.Wilcoxonmatched pairs signed rank testwas used to com-
pare paired TIF and plasma concentrations, and the non-parametric
Mann–Whitney test to compare concentrations in early and advanced
stage patients. To evaluate whether the values were changing with
stage, linear regression for concentrations and linear regression on log-
transformed values for ratios were performed.
3. Results
Selected proteins were measured in matched TIF and plasma from
31 patients. All patients had either serous (n = 19), endometrioid
(n = 9) or clear cell (n = 3) tumors. International Federation of Gyne-
cology and Obstetrics (FIGO) stage of disease ranged from IA to IV, with
an even number of samples from patients with advanced (n= 16) and
early stage (n = 15) disease (Table 1). The grades ranged from high to
low differentiation, with the majority of samples having low differenti-
ation (grade 3, n=18, Table 1). Asciteswas investigatedwhen available
(n= 4). Histological data are given in Table 1. Having limited access to
fresh early stage tumors we isolated fluid from frozen and thawed
tumor samples for 11 early stage tumors. To assess the influence of
Table 1
Patient datawith histological subtype, FIGO stage, grade, CA-125 concentrations in tumor interstitial fluid (TIF), ascites and plasma and VEGF-A and osteopontin concentrations (duplicate
measurements shown separately) in TIF and plasma.
Patient no. Subtype Stage Grade CA-125 VEGF-A Osteopontin
TIF Ascites Plasma TIF Plasma TIF Plasma
1 CC IA 3 36,620 41.2 122 114 2.08 1.90 191 178
2a END IA 1 627,800 435 141 150 0.77 0.91 220 212 97.6 97.5
3a END IA 2 7670 165 278 273 3890 4236
4a END IA 2 2300 29.6 151 136 0.99 1.11 843 653 211 238
5a END IA 2 2700 33.2 1012 1035 3.07 2.55 390 376 143 155
6 SERb IA 2 2,823,450 116 36.8 34.1 0.87 1.07 3424 3571 80.3 83.0
7a SER IA 3 132,500 59.6 530 514 2.97 2.91 5306 5658 97.9 101
8a END IC 2 348,400 30.8 177 167 2.15 2.07 1633 2100 188 180
9a END IC 2 1,853,000 334 25.2 28.9 2.45 2.63 363 388 56.5 54.2
10a END IC 2 365,800 524 5.74 4.61 0.54 0.31 629 487 88.0 110
11a END IC 3 370,900 562 219 227 2.05 2.22 4981 5233 179 181
12a SER IC 1 925,300 242 156 186 0.55 0.44 1540 1507 123 132
13a SER IC 3 240,100 1239 48.0 51.4 1.75 1.69 2790 1883 183 188
14 CC IIA na 130,400 442 142 144 2.51 2.37 4178 4526 371 384
15 SER IIB 3 389,400 74.8 148 130 0.12 0.14 107 118
16 END IIIB 3 31,395 1814 375 426 435 2.48 2.31 1327 1401 83.2 89.2
17 SER IIIC 3 191,800 1066 413 38.6 39.2 1.92 2.31 2119 2164 109 116
18 SER IIIC 3 3260 1650 596 6.39 4.75 3.02 2.94 194 214 268 273
19 SER IIIC 3 49,280 3066 213 211 1.77 1.60 6825 7258 344 350
20 SER IIIC 3 125,200 1102 41.7 48.2 1.06 0.90 5266 5422 193 214
21 SER IIIC 3 5810 1937 187 228 0.96 0.68 6690 6597 350 351
22 SER IIIC 3 76,370 58.8 2.71 3.95 0.91 0.92 70.9 81.2 142 149
23 SER IIIC 3 610 427 197 193 1.33 1.09 5678 5236 146 140
24 SER IIIC 3 174,400 85.2 68.5 56.3 1.96 1.92 1859 2114 227 238
25 SER IIIC 3 8960 139.2 158 138 0.29 0.10 5315 5038 87.2 79.6
26 SER IIIC 3 173,800 2280 31.4 31.1 0.42 0.31 2578 2534 191 155
27 SER IIIC na 12,700 136 34.1 35.4 3.84 4.06 1411 1321 191 173
28 CC IV na 5290 222 70.2 60.1 1.18 1.14 7411 6406 270 290
29 SER IV 2 2480 93.0 12.8 12.2 3.64 3.58 994 937 400 408
30 SER IV 3 71,560 603 505 47.8 44.0 2.06 1.84 1149 1241 389 429
31 SER IV na 461,400 1466 123 125 0.31 0.56 5641 5570 170 194
Across all samples investigated
Median 125,200 1358 334 124 1.70 2141 181
Minimum 610 603 29.6 3.33 0.13 76.1 55.3
Maximum 2,823,450 1814 3066 1023 3.95 7042 409
SER: serous adenocarcinoma, CC: clear cell adenocarcinoma, END: endometrioid adenocarcinoma.
a Biobank samples.
b Areas of tumor with borderline serous histology.
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cation of the selected proteins, two samples, wherefluid fromboth fresh
and frozen tissue was available, were analyzed in parallel.
3.1. CA-125
CA-125 is the reference biomarker for ovarian cancer. The majority
of CA-125-measurements in plasma, ranging from 30 to 3066 U/ml
with a median of 334 U/ml (Fig. 1A), exceeded the clinical threshold
of 35 U/ml, while three samples had borderline concentrations (30, 31
and 33 U/ml). Ascites CA-125-levels were between 1.2- and 4-fold
that of plasma, with a median value of 1358 U/ml not different from
the paired plasma samples (Fig. 1A). In TIF, the concentration ranged
from 610 to 2,823,450 U/ml with a median of 125,200 U/ml (Fig. 1A).
When comparing samples isolated from frozen and thawed tissue, the
concentration of CA-125 was increased 1.6 (sample 20) and 3.2 fold
(sample 22) relative to TIF isolated from fresh samples. Moreover,
there was a significantly higher concentration in TIF in stages I and II
compared to III and IV (p= 0.019),whereas this relationshipwas oppo-
site, and borderline significant in plasma (p = 0.06). Linear regression
showed that CA-125 concentration decreased significantly in TIF
(p = 0.03), and increased in plasma with borderline significance
(p = 0.053) with increasing FIGO-stage (Fig. 2A).
Asmight be expected in a situationwith local production, the TIF CA-
125-concentration was significantly higher than in the corresponding
plasma samples (p b 0.0001), with a 1.4- to 24,256-fold increase(median = 194). The mean TIF-to-plasma ratio was 1985, comparable
with the 1000–1500-fold gradient predicted by Ahn et al. [4,5],
confirming that there is a substantial up-concentration of the locally
produced CA-125 in TIF compared with plasma, including in early
stage disease. The TIF-to-plasma ratios correlated strongly to stage
(p = 0.0006, y = 4482e−1.12x, R2 = 0.29, Fig. 2B).
3.2. VEGF-A
VEGF-A is an angiogenesis promoter with a central role in tumor
development, and thus of interest to quantify in TIF. The concentration
of VEGF-A in plasma ranged from 0.13 to 3.9 ng/ml, with a median of
1.7 ng/ml (Fig. 1B). TIF had significantly increased levels of VEGF-A
(p b 0.0001, Wilcoxon matched pairs signed rank test), ranging from
3.3 to 1023 ng/ml, with a median concentration of 124 ng/ml
(Fig. 1B). The TIF-to-plasma ratio of VEGF was smaller than for CA-
125, ranging from 1.9 to 1040, and was not related to the stage of dis-
ease (data not shown). The concentrations of VEGF-A in TIF isolated
from fresh and frozen tissue were highly similar, with a tissue sample
from frozen tissue containing 91 and 102% of the VEGF-A concentration
in TIF, suggesting that the tumor cells are not a major source of VEGF-A.
3.3. Osteopontin
Osteopontin has earlier been suggested as a biomarker for ovarian
cancer [18,20]. The concentrations ranged from 55 to 409 ng/ml
21H. Haslene-Hox et al. / BBA Clinical 2 (2014) 18–23(median = 181 ng/ml) in plasma (Fig. 1C), whereas in TIF, osteopontin
levels ranged from 76 to 7042 ng/ml (median = 2141 ng/ml, Fig. 1C),
significantly increased compared with plasma (p b 0.0001, Wilcoxon
matched pairs signed rank test). The TIF-to-plasma concentration gradi-
ent ranged from 0.5 to 62, with a median of 12, and was not related to
stage (data not shown).
3.4. Tissue elution
We measured the CA-125 in eluate after 1 and 24 h to 6164 and
10,837 U/ml respectively, with the corresponding TIF of 130,400 U/mlFig. 1. CA-125, VEGF-A and osteopontin in tumor interstitial fluid (TIF), ascites and
plasma. Concentration of A) CA-125 (Units ml−1); B) VEGF-A (ng ml−1); and
C) osteopontin (ng ml−1) in TIF, ascites (for CA-125) and plasma from patients
with epithelial ovarian carcinomas. Values are for individual tumors and also show
mean ± SEM. ***: p = 0.0001 (Wilcoxon matched pairs signed rank test).
Fig. 2. CA-125 concentration related to tumor stage. A) CA-125 concentration (unitsml−1)
in tumor interstitial fluid (TIF, ●) and in plasma (○) according to FIGO tumor stage.
Linear regressions (solid lines) for TIF: y=−203,892x+ 848,009, R2= 0.15 and plasma:
y = 224.3x − 34.46, R2 = 0.12, slopes being different from zero for TIF (p = 0.03) and
borderline significant for plasma (p = 0.053). B) Ratio of CA-125 concentration in TIF
and plasma in individual tumors according to FIGO tumor stage. Exponential regression
(solid line): y = 4482e−1.12x, R2 = 0.29, with 95% confidence interval (dashed lines),
slope significantly different from zero (p = 0.0006).(Patient no. 14, Table 1). To be able to estimate the concentration of
CA-125 in TIF after elution in PBS, we assumed that all CA-125 present
in eluate originated from the extracellular compartment of the tumor,
being ~50% of tumor wet weight [7]. Using this approach, the undiluted
extracellular CA-125 concentration was calculated at 45,522 and
67,955 U/ml for E1 and E24 respectively. The increase in CA-125 after
24 h compared with 1 h indicates that CA-125 may not have been
completely eluted from the tissue after 1 h, although the extended
time of elution may result in increased proteolytic cleavage of mem-
brane bound CA-125 that is released to the elution buffer.4. Discussion
Here we have determined the magnitude of a previously assumed
TIF-to-plasma gradient, central for proximal fluid biomarker discovery.
We have quantified the concentration gradient of three proteins
relevant for ovarian cancer, CA-125, osteopontin and VEGF-A, and dem-
onstrate a substantial CA-125 concentration even in early stage tumors,
with a TIF-to-plasma ratio strongly correlated to stage.
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The origin of the fluid sample isolated from human ovarian carcino-
mas has earlier been verified to be representative for tumor interstitial
fluid [24] when isolated from fresh samples. However, due to a low
number of early stage fresh samples available, frozen biobank material
was also used. Previously we have shown that samples that have been
frozen and thawed have a contribution of approximately 20% intracellu-
lar fluid to the isolated sample [24]. Comparing parts from the same
tumor samples that were either processed fresh or after freezing dem-
onstrated a CA-125-concentration 1.6 to 3.2 times higher in the latter
case. Although two samples are not enough for statistical analysis,
these findings can indicate a substantial intracellular concentration of
CA-125 that is added to the isolated fluid consistent with local produc-
tion of CA-125 in the tissue. Calculations based on values obtained from
frozen biobank samples may thus overestimate CA-125-concentration.
To control whether an overestimation of these values affects the statis-
tical analysis, calculations were repeated with the measured CA-125
concentrations multiplied by the two frozen samples' average increase
of 2.4. Both with and without this correction the main conclusions
remained unchanged.
In tissue arrays performed on 382 ovarian tumors with matched
serum samples, Høgdall et al. [15] found that expression of CA-125
in tissue, but not serum, had prognostic value. Although moderate,
we found that CA-125-concentrations in TIF decreased in advanced
stage disease. The decrease in TIF CA-125-concentration in advanced
stage disease may result from a more heterogeneous tumor cell pop-
ulation as the tumor grows and contributions to TIF from stromal
cells.
We found a substantial TIF-to-plasma ratio that correlated strongly
with stage, yet decreasing in advanced stage tumors. A likely explana-
tion is that during tumor growth, the amount of CA-125 secreted to
plasma will increase provided that there is a similar interstitial concen-
tration of CA-125 and there is no increase in clearance from plasma. As
the tumor volume increases, CA-125 can be released from a larger fluid
compartment into the unchanged circulating blood volume. The net
result will be a reduced TIF-to-plasma ratio as the tumor grows and a
higher TIF-to-plasma ratio when the total tumor burden is low. Since
there is a parallel increase in cell mass and interstitial volume during
tumor growth, the concentration of CA-125 in plasma is most likely
mainly decided by tumormass, in agreement with the present observa-
tion (Fig. 2).
It should be noted, though, that the total tumor burden in advanced
stage disease will also depend on metastases that may or may not
produce CA-125. These metastases will contribute to the protein con-
centration in plasma, but not in TIF from the primary tumor site.
When considering change in CA-125 concentrations related to stage,
it is important to note that the endometrioid and serous subtypes of
ovarian cancer is differently represented in the early- and advanced-
stage groups, with endometrioid tumors predominantly present at
earlier stages. Recently, a classification of ovarian cancer in two types
has been suggested; type I representing slow-growing cancers with
good prognosis, such as low-grade serous, low-grade endometrioid,
clear cell and mucinous tumors, and type II being more aggressive,
including high-grade serous, high-grade endometrioid and undifferen-
tiated tumors [26]. It has also been demonstrated by Köbel et al. [27]
that a number of biomarkers have different levels in plasma between
subtypes but not necessarily between disease stages within each
subtype. Thus, care should be taken when considering the change in
protein concentrations according to stage in a cohort includingmultiple
subtypes. However, the levels of CA-125 were practically similar in
serous compared with both clear cell and endometrioid subtypes [27].
Our cohort also includes high-grade tumors that may be classified as
type II in the lower stages. CA-125 concentrations will likely reflect dis-
ease development rather than being subtype-specific, but care should
be taken when extrapolating to other biomarkers.4.2. VEGF-A
The angiogenesis related protein VEGF-A had lower TIF-to-plasma
gradients compared with CA-125 (Fig. 1B). The concentrations of
VEGF-A in TIF isolated from fresh and frozen tissuewere practically sim-
ilar, with a tissue sample from frozen tissue containing 91 and 102% of
the VEGF-A concentration in TIF. Even though there were two observa-
tions only, these findings suggest that the rupture of tumor cells does
not change the concentration of VEGF-A in the isolated fluid, and that
VEGF-A enters the tumor microenvironment both from tumor cells
and the circulation.
The quantification of VEGF-A in TIF can be used in the modeling of
tumor biology [28],where suchquantitative data is lacking. Themeasured
TIF concentration of VEGF-A (3.3–1023ng/ml) is higher than the value es-
timated by Finley et al. of 1125 pg/ml [28], but within the range found in
tumor extracts (5.5 to 7600 ng/ml, Supplementary Table 1 in [28]).
Intratumoral VEGF-A in tumor fluid isolated bymicrodialysis has pre-
viously been reported to 6 pg/ml (n = 10) with similar concentrations
measured in plasma (3.67 pg/ml) [29]. The substantially lowermeasured
concentration in dialysate compared to ourmeasurements is likely due to
the sieving effect and low recovery of proteins in microdialysis [6,7].
4.3. Osteopontin
Osteopontin is a small integrin-binding glycophosphoprotein se-
creted by a variety of cell types, including osteoclasts, endothelial
cells, epithelial cells, and activated immune cells, and can act as a mod-
ulator of cell adhesion aswell as an autocrine and paracrine factor by in-
teraction with e.g. integrins [19,22]. When measuring osteopontin in
frozen and thawed tissue we found concentrations 29% and 43% of the
values measured in fresh TIF. Thus, fluid not containing osteopontin
was admixed into the isolated fluidwhen using frozen tissue, indicating
that the concentration of osteopontin is low in these two tumors. The
decrease in osteopontin concentration after one freeze/thaw cycle
could be restricted to the two samples tested in both conditions, but
as these two samples showed two of the highest concentrations for
osteopontin in both TIF and plasma it is unlikely that they originated
from osteopontin-negative patients. The two patients may however
have osteopontin-producing metastases that contribute to a high plas-
ma concentration, with the primary tumor producing small amounts
of the protein.
The osteopontin TIF-to-plasma ratios were substantially lower than
the corresponding ratios for both VEGF-A and CA-125. Our findings
may indicate systemic production of osteopontin rather than local,
and the tumor is supplied with osteopontin mainly from the blood
stream. Another explanation for the low ratios compared with CA-125
and VEGF can be that osteopontin has a short half-life in the tumor
environment, resulting in a fast breakdown, and low steady-state con-
centrations of the protein. This may question the value of osteopontin
as a specific ovarian cancer biomarker [18,20]. Nevertheless, the ratio
between TIF and plasma is high for several patients and can indicate
that osteopontin may accumulate in the tumor microenvironment.
For a definite conclusion to be drawn about the relation between
both osteopontin andVEGF-Awith stage, a larger patient cohort, includ-
ing documentation of tumor burden and residual disease is needed.
4.4. Tissue elution
Tissue elution is awidely utilized technique for TIF isolation [25] that
does not give an absolute concentration of the substance of interest in
TIF because of dilution with PBS [25]. Furthermore, the extracellular
CA-125 concentration estimated from eluate was lower than that mea-
sured in TIF extracted by centrifugation. The explanation is probably
that CA-125 cannot distribute in the total extracellular fluid volume
due to volume exclusion [30,31] as earlier demonstrated for proteins
such as albumin that can distribute in approximately 50% of the
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equilibration with buffer as well as volume exclusion will result in the
underestimation of the CA-125 concentration in TIF based on elution
data. If we, however, take these considerations into account, and as-
sume that CA-125 can distribute in a volume similar to albumin, the
concentration of CA-125 estimated by tissue elution at both time points
approach the concentration measured in TIF isolated by centrifugation.
By calculating the total extracellular volume of the ovarian tumors and
the available distribution volume of similar sized plasma proteins, the
correct concentration of CA-125, or other proteins may be calculated
from eluate data [32].
Sedlaczek et al. [33] investigated CA-125 in cyst fluid from ovarian tu-
mors, ascites and plasma. Cyst fluid differs from TIF because it originates
from a sequestered space not in direct contact with the circulation,
whereas TIF originates from filtered fluid and is returned to the blood cir-
culation by lymph having percolated tumor and stromal cells. Sedlaczek
and co-workers found median levels of CA-125 in serum from serous
and endometrioid carcinomas of 696 and 661 U/ml respectively; some-
what higher, but within the same range as our data. The range of CA-
125 was smaller in cyst fluid than in TIF, mainly because of one patient
in our set who had an extremely high CA-125-level in TIF (2.82 ⋅ 106 U/
ml), and themedian values (44,850 and 32,150U/ml in cystfluid from se-
rous and endometrioid tumors, respectively) were lower than our mea-
sured levels of CA-125 in TIF (125,200 U/ml), suggesting that cyst fluid
may have a protein composition slightly lower than TIF.
5. Conclusions
To our knowledge our results represent the first successful efforts to
quantify the concentration gradient between tumor microenvironment
and plasma in human samples. Our method to quantify this gradient
may significantly contribute to the applicability of proximal fluids and
TIF for biomarker discovery. The determination of the locally produced
biomarker CA-125 in TIF comparedwith plasma exemplifies the advan-
tage of using TIF as a source for biomarker and therapeutic target
discoveries. Proteins locally produced in the tumor will have dramati-
cally elevated concentrations in TIF compared with plasma, more so in
early stages, and the likelihood of finding tumor-specific proteins can
be increased in such samples. On the other hand, the demonstration of
lower ratios for VEGF-A and osteopontin suggests a less tumor-specific
production. These proteins are elevated in plasma from ovarian cancer
patients [17,19], as they are for many other cancers, and are thus likely
primarily coupled to the systemic response to cancer and only second-
arily to the tumor microenvironment.
The use of TIF-to-plasma ratios as a tool to assess the suitability of
novel biomarkers may assist in the validation and translation of novel
biomarkers for ovarian as well as other cancers, and should be further
explored.
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